<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>0864-2176</journal-id>
<journal-title><![CDATA[Revista Cubana de Oftalmología]]></journal-title>
<abbrev-journal-title><![CDATA[Rev Cubana Oftalmol]]></abbrev-journal-title>
<issn>0864-2176</issn>
<publisher>
<publisher-name><![CDATA[Editorial Ciencias Médicas]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S0864-21762021000400011</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Novedades del glaucoma en tiempos de COVID-19]]></article-title>
<article-title xml:lang="en"><![CDATA[News about glaucoma in the time of COVID-19]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Arzuaga Hernández]]></surname>
<given-names><![CDATA[Elizabeth]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Fumero González]]></surname>
<given-names><![CDATA[Francisco Y.]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Batista Peña]]></surname>
<given-names><![CDATA[Maikel]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Domínguez Randulfe]]></surname>
<given-names><![CDATA[Marerneda]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Pérez Rangel]]></surname>
<given-names><![CDATA[Yantsy]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Instituto Cubano de Oftalmología &#8220;Ramón Pando Ferrer&#8221;  ]]></institution>
<addr-line><![CDATA[ La Habana]]></addr-line>
<country>Cuba</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>12</month>
<year>2021</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>12</month>
<year>2021</year>
</pub-date>
<volume>34</volume>
<numero>4</numero>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://scielo.sld.cu/scielo.php?script=sci_arttext&amp;pid=S0864-21762021000400011&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.sld.cu/scielo.php?script=sci_abstract&amp;pid=S0864-21762021000400011&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.sld.cu/scielo.php?script=sci_pdf&amp;pid=S0864-21762021000400011&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[RESUMEN El impacto de la COVID-19 en la atención médica dominó las noticias en 2020, incluida la atención del glaucoma. Sin embargo, el reciente cambio de paradigma en la terapia de esta patología hacia una intervención más temprana, un mejor manejo del cumplimiento del paciente y un nuevo enfoque en abordar la patología real, continuó avanzando en este periodo con la aprobación de nuevos medicamentos, productos biológicos y dispositivos, que significaron avances en la atención médica. En este artículo, pretendemos reflexionar sobre los logros obtenidos en el año 2020 en el tratamiento del glaucoma, así como brindar una descripción general de los hallazgos más notables. Se realizó una búsqueda sistemática de la literatura científica de mayor impacto. Se limitó la búsqueda por tipo de diseño (revisiones, series de casos, estudios descriptivos, analíticos y experimentales, metanálisis). No se tuvo en cuenta el idioma de la publicación.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[ABSTRACT The impact of COVID-19 on medical care was ever-present in the news during the year 2020, and glaucoma care was not an exception. However, the recent paradigm switch in the treatment of this condition towards earlier intervention, better management of patient compliance, and a new approach in addressing the actual disorder, continued to gain ground in this period with the approval of new drugs, biological products and devices leading to the advancement of medical care. The purpose of the study was to reflect on the progress achieved in the treatment of glaucoma in the year 2020, and provide a general description of the most notable findings. A systematic search was conducted in the highest-impact scientific literature. The search was limited to reviews, case series, descriptive, analytical and experimental studies, and meta-analyses. The language of publication was not taken into account.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[Glaucoma]]></kwd>
<kwd lng="es"><![CDATA[innovaciones]]></kwd>
<kwd lng="es"><![CDATA[novedades]]></kwd>
<kwd lng="es"><![CDATA[avances médicos]]></kwd>
<kwd lng="es"><![CDATA[terapia médica]]></kwd>
<kwd lng="es"><![CDATA[tratamiento quirúrgico]]></kwd>
<kwd lng="en"><![CDATA[Glaucoma]]></kwd>
<kwd lng="en"><![CDATA[innovations]]></kwd>
<kwd lng="en"><![CDATA[news]]></kwd>
<kwd lng="en"><![CDATA[medical advances]]></kwd>
<kwd lng="en"><![CDATA[medical therapy]]></kwd>
<kwd lng="en"><![CDATA[surgical treatment]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kim]]></surname>
<given-names><![CDATA[CY]]></given-names>
</name>
<name>
<surname><![CDATA[Park]]></surname>
<given-names><![CDATA[KH]]></given-names>
</name>
<name>
<surname><![CDATA[Ahn]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Ahn]]></surname>
<given-names><![CDATA[MD]]></given-names>
</name>
<name>
<surname><![CDATA[Cha]]></surname>
<given-names><![CDATA[SC]]></given-names>
</name>
<name>
<surname><![CDATA[Kim]]></surname>
<given-names><![CDATA[HS]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Treatment patterns and medication adherence of patients with glaucoma in South Korea]]></article-title>
<source><![CDATA[Br J Ophthalmol]]></source>
<year>2017</year>
<volume>101</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>801-7</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Cvenkel]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Kolko]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Current medical therapy and future trends in the management of glaucoma treatment]]></article-title>
<source><![CDATA[J Ophthalmol]]></source>
<year>2020</year>
<volume>2020</volume>
</nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Shirley]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Bimatoprost implant first approval]]></article-title>
<source><![CDATA[Drugs Aging]]></source>
<year>2020</year>
<volume>37</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>457-62</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lee]]></surname>
<given-names><![CDATA[SS]]></given-names>
</name>
<name>
<surname><![CDATA[Dibas]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Almazan]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Robinson]]></surname>
<given-names><![CDATA[MR]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Dose-response of intracameral bimatoprost sustained-release implant and topical bimatoprost in lowering intraocular pressure]]></article-title>
<source><![CDATA[J Ocul Pharmacol Ther]]></source>
<year>2019</year>
<volume>35</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>138-44</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Medeiros]]></surname>
<given-names><![CDATA[FA]]></given-names>
</name>
<name>
<surname><![CDATA[Walters]]></surname>
<given-names><![CDATA[TR]]></given-names>
</name>
<name>
<surname><![CDATA[Kolko]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Coote]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Bejanian]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Goodkin]]></surname>
<given-names><![CDATA[ML]]></given-names>
</name>
<name>
<surname><![CDATA[Guo]]></surname>
<given-names><![CDATA[Q]]></given-names>
</name>
<name>
<surname><![CDATA[Zhang]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Robinson]]></surname>
<given-names><![CDATA[MR]]></given-names>
</name>
<name>
<surname><![CDATA[Weinreb]]></surname>
<given-names><![CDATA[RN]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Phase 3, Randomized, 20-Month Study of Bimatoprost Implant in Open-Angle Glaucoma and Ocular Hypertension (ARTEMIS 1)]]></article-title>
<source><![CDATA[Ophthalmology]]></source>
<year>2020</year>
<volume>127</volume>
<numero>12</numero>
<issue>12</issue>
<page-range>1627-41</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Craven]]></surname>
<given-names><![CDATA[ER]]></given-names>
</name>
<name>
<surname><![CDATA[Walters]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Christie]]></surname>
<given-names><![CDATA[WC]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[24-month phase I/II clinical trial of bimatoprost sustained-release implant (Bimatoprost SR) in glaucoma patients]]></article-title>
<source><![CDATA[Drugs]]></source>
<year>2020</year>
<volume>80</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>167-79</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lewis]]></surname>
<given-names><![CDATA[RA]]></given-names>
</name>
<name>
<surname><![CDATA[Christie]]></surname>
<given-names><![CDATA[WC]]></given-names>
</name>
<name>
<surname><![CDATA[Day]]></surname>
<given-names><![CDATA[DG]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Bimatoprost sustained-release implants for glaucoma therapy 6-month results from a phase I/II clinical trial]]></article-title>
<source><![CDATA[Am J Ophthalmol]]></source>
<year>2017</year>
<volume>175</volume>
<page-range>137-47</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Seal]]></surname>
<given-names><![CDATA[JR]]></given-names>
</name>
<name>
<surname><![CDATA[Robinson]]></surname>
<given-names><![CDATA[MR]]></given-names>
</name>
<name>
<surname><![CDATA[Burke]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Intracameral sustained-release bimatoprost implant delivers bimatoprost to target tissues with reduced drug exposure to off-target tissues]]></article-title>
<source><![CDATA[J Ocul Pharmacol Ther]]></source>
<year>2019</year>
<volume>35</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>50-7</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ibach]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<source><![CDATA[Interim results of a prospective phase II study of travoprost intraocular implants]]></source>
<year>2018</year>
<publisher-loc><![CDATA[San Antonio, Texas ]]></publisher-loc>
<publisher-name><![CDATA[American Academy of Optometry Annual Meeting]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rady]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<source><![CDATA[A novel, long-term, sustainable drug delivery platform]]></source>
<year>2020</year>
<publisher-loc><![CDATA[San Francisco ]]></publisher-loc>
<publisher-name><![CDATA[Glaucoma 360: New Horizons Forum]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gazzard]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Konstantakopoulou]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Garway-Heath]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Garg]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Vickerstaff]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Hunter]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Selective laser trabeculoplasty versus eye drops for first-line treatment of ocular hypertension and glaucoma (LiGHT) a multicentre randomised controlled trial]]></article-title>
<source><![CDATA[The Lancet]]></source>
<year>2019</year>
<volume>393</volume>
<numero>10180</numero>
<issue>10180</issue>
<page-range>1505-16</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Belkin]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Geffen]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Ofir]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Kaplan Messas]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Barkana]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Belkin]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Direct trans-scleral selective laser trabeculoplasty (SLT) without a gonioscopy lens]]></article-title>
<source><![CDATA[Invest Ophthalmol Vis Sci]]></source>
<year>2014</year>
<volume>55</volume>
<numero>13</numero>
<issue>13</issue>
<page-range>819</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sacks]]></surname>
<given-names><![CDATA[ZS]]></given-names>
</name>
<name>
<surname><![CDATA[Dobkin-Bekman]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Geffen]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Goldenfeld]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Belkin]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Non-contact direct selective laser trabeculoplasty light propagation analysis]]></article-title>
<source><![CDATA[Biomed Opt Express]]></source>
<year>2020</year>
<volume>11</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>2889-904</page-range></nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Goldenfeld]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Belkin]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Dobkin-Bekman]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Sacks]]></surname>
<given-names><![CDATA[Z]]></given-names>
</name>
<name>
<surname><![CDATA[Meirovitch]]></surname>
<given-names><![CDATA[SB]]></given-names>
</name>
<name>
<surname><![CDATA[Geffen]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Automated direct selective laser trabeculoplasty first prospective clinical trial]]></article-title>
<source><![CDATA[Trans Vis Sci Tech]]></source>
<year>2021</year>
<volume>10</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>1-11</page-range></nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Roy]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Villamarin]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Stergiopulos]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Bigler]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Guidotti]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Stergiopulos]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Kniestedt]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Mermoud]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Initial Clinical Results of the eyeWatch a New Adjustable Glaucoma Drainage Device Used in Refractory Glaucoma Surgery]]></article-title>
<source><![CDATA[J Glauc]]></source>
<year>2019</year>
<volume>28</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>452-8</page-range></nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Villamarin]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Roy]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Bigler]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Stergiopulos]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[A new adjustable glaucoma drainage device]]></article-title>
<source><![CDATA[Invest Ophthalmol Vis Sci]]></source>
<year>2014</year>
<volume>55</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>1848-52</page-range></nlm-citation>
</ref>
<ref id="B17">
<label>17</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ammar]]></surname>
<given-names><![CDATA[DA]]></given-names>
</name>
<name>
<surname><![CDATA[Seibold]]></surname>
<given-names><![CDATA[LK]]></given-names>
</name>
<name>
<surname><![CDATA[Kahook]]></surname>
<given-names><![CDATA[MY]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Preclinical investigation of goniotomy using four different techniques]]></article-title>
<source><![CDATA[Clin Ophthalmol]]></source>
<year>2020</year>
<volume>28</volume>
<numero>14</numero>
<issue>14</issue>
<page-range>3519-25</page-range></nlm-citation>
</ref>
<ref id="B18">
<label>18</label><nlm-citation citation-type="journal">
<collab>Eurotimes</collab>
<article-title xml:lang=""><![CDATA[A Cataract Surgeon's Guide to iStent inject W: Improving outcomes and quality of life in cataract patients with mild-to-moderate open-angle glaucoma]]></article-title>
<source><![CDATA[Eurot]]></source>
<year>2019</year>
<numero>^sSuppl</numero>
<issue>^sSuppl</issue>
<supplement>Suppl</supplement>
<page-range>1-10</page-range></nlm-citation>
</ref>
<ref id="B19">
<label>19</label><nlm-citation citation-type="confpro">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Cela]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<source><![CDATA[Safety and efficacy of iStent Inject(r) trabecular micro-bypass stents during phacoemulsification for open-angle glaucoma associated with cataract]]></source>
<year>2019</year>
<conf-name><![CDATA[ 37Congress of the ESCRS]]></conf-name>
<conf-loc> </conf-loc>
<publisher-loc><![CDATA[Francia, Paris ]]></publisher-loc>
</nlm-citation>
</ref>
<ref id="B20">
<label>20</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Marko]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Efficacy and adverse event profile of the istent and istent inject trabecular micro-bypass for open-angle glaucoma A Meta-analysis]]></article-title>
<source><![CDATA[J Curr Glauc Pract]]></source>
<year>2018</year>
<volume>12</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>67-84</page-range></nlm-citation>
</ref>
<ref id="B21">
<label>21</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Pinchuk]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Riss]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Batlle]]></surname>
<given-names><![CDATA[JF]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The development of a micro-shunt made from poly (styrene-block-isobutylene-block-styrene) to treat glaucoma]]></article-title>
<source><![CDATA[J Biomed Mater Res B Appl Biomater]]></source>
<year>2017</year>
<volume>105</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>211-21</page-range></nlm-citation>
</ref>
<ref id="B22">
<label>22</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kerr]]></surname>
<given-names><![CDATA[NM]]></given-names>
</name>
<name>
<surname><![CDATA[Ahmed]]></surname>
<given-names><![CDATA[IIK]]></given-names>
</name>
<name>
<surname><![CDATA[Pinchuk]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Sadruddin]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
<name>
<surname><![CDATA[Palmberg]]></surname>
<given-names><![CDATA[PF]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[PRESERFLO MicroShunt]]></article-title>
<source><![CDATA[Minim Inv Glauc Surg]]></source>
<year>2020</year>
<page-range>91-103</page-range></nlm-citation>
</ref>
<ref id="B23">
<label>23</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Batlle]]></surname>
<given-names><![CDATA[JF]]></given-names>
</name>
<name>
<surname><![CDATA[Corona]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Albuquerque]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Long-term results of the PRESERFLO(r) MicroShunt in Patients with Primary Open-angle Glaucoma from a Single-center Non-randomized Study]]></article-title>
<source><![CDATA[J Glauc]]></source>
<year>2021</year>
<volume>30</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>281-6</page-range></nlm-citation>
</ref>
<ref id="B24">
<label>24</label><nlm-citation citation-type="book">
<collab>ClinicalTrials.gov</collab>
<source><![CDATA[NCT02177123. Post market study of the InnFocus MicroShunt]]></source>
<year>2018</year>
<publisher-name><![CDATA[ClinicalTrials.gov]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B25">
<label>25</label><nlm-citation citation-type="book">
<collab>ClinicalTrials.gov</collab>
<source><![CDATA[NCT00772330. Clinical study of the safety and performance of the Miami InnFocus Drainage Implant to relieve glaucoma symptoms]]></source>
<year>2019</year>
<publisher-name><![CDATA[ClinicalTrials.gov]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B26">
<label>26</label><nlm-citation citation-type="book">
<collab>ClinicalTrials.gov</collab>
<source><![CDATA[NCT01881425. InnFocus MicroShunt versus trabeculectomy study (IMS)]]></source>
<year>2019</year>
<publisher-name><![CDATA[ClinicalTrials.gov]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B27">
<label>27</label><nlm-citation citation-type="book">
<collab>iStent infinite</collab>
<source><![CDATA[Powerful Standalone MIGS Indication]]></source>
<year>2021</year>
<publisher-name><![CDATA[Glaukos Corporation]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B28">
<label>28</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Keel]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The eye in artificial intelligence in Ophthalmology]]></article-title>
<source><![CDATA[Clin Exp Ophthalmol]]></source>
<year>2019</year>
<volume>47</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>5-6</page-range></nlm-citation>
</ref>
<ref id="B29">
<label>29</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mayro]]></surname>
<given-names><![CDATA[EL]]></given-names>
</name>
<name>
<surname><![CDATA[Wang]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Elze]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Pasquale]]></surname>
<given-names><![CDATA[LR]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The impact of artificial intelligence in the diagnosis and management of glaucoma]]></article-title>
<source><![CDATA[Eye (Lond)]]></source>
<year>2020</year>
<volume>34</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>1-11</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
